Relay Therapeutics CFO Sells Shares Worth $350K via Pre-Arranged Trading Plan
Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics (NASDAQ:RLAY), sold 17,717 shares for approximately $349,734 on August 14, 2026. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan established in October 2025 and is considered routine given the structured nature of such insider sales. Following this sale, Catinazzo retained ownership of 140,568 shares with an estimated market value of $2.9 million as of August 17, 2026 (share price: $20.67). The company's stock has appreciated by over 485% in the past year despite a trailing twelve-month net loss of $286 million on revenue of just $10.3 million. Relay Therapeutics remains focused on developing small-molecule therapies for oncology and genetic diseases, with its lead candidate RLY-4008 currently in clinical trials.
